Acies Bio has started constructing a new facility with advanced fermentation and downstream processing (DSP) capabilities. The project features a 30 m³ bioreactor, the largest in the company’s history. This expansion marks a significant step toward increasing large-scale biomanufacturing capacity from the current 10 m³ size.
The new infrastructure is expected to be completed by Q4 2026, supporting the company’s vision of flexible biomanufacturing.
Acies Bio focuses on delivering adaptable bioprocessing solutions. The expansion integrates new capacity with existing R&D and pilot infrastructure. This will enable end-to-end biomanufacturing services across Europe, supporting innovation and commercialization.
Štefan Fujs, CEO of Acies Bio, stated, “Europe needs flexible biomanufacturing infrastructure to bridge innovation and market readiness.” He emphasized the importance of tailored solutions for emerging bio-based technologies. The expansion strengthens Acies Bio’s role in supporting Europe’s bioeconomy and sustainability goals.
Mirjan Švagelj, Director of Bioprocessing, added, “The new facility with a 30 m³ bioreactor doubles our fermentation capacity to 72 m³.” Alongside existing 8 m³ and 3 m³ systems, this upgrade increases throughput and project complexity handling. It positions Acies Bio to serve larger, more demanding biomanufacturing projects.
With over 20 years of R&D expertise, Acies Bio helps partners improve yield, productivity, and cost-efficiency. Its iterative approach reduces costs of goods sold (COGS) and enhances process optimization. A partnership with Plant Health Care exemplifies this, demonstrating reliable, scalable biomanufacturing.
Meagan Osborn, Head of Supply Chain at Plant Health Care, praised Acies Bio’s reliability and technical rigor. The expansion underscores Acies Bio’s commitment to advancing flexible biomanufacturing in Europe. It aims to accelerate the transition to a sustainable, bio-based future.
